iRadimed Corporation's stock soared 5.20% during intraday trading on Friday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.

The MRI-compatible medical device maker reported quarterly adjusted earnings of $0.49 per share, beating the consensus estimate of $0.45. Revenue for the quarter rose 13% year-over-year to $22 million, also surpassing the $21.3 million analysts had forecast. The company attributed this strong growth primarily to the successful commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, which has generated strong early order activity with larger order sizes than the prior-generation platform.

Adding to investor confidence, iRadimed reaffirmed its full-year 2026 guidance, expecting revenue of $91 million to $96 million and adjusted earnings per share of $2.06 to $2.21. The company also declared a regular quarterly cash dividend of $0.20 per share. The combination of an earnings beat, robust revenue growth driven by a new product, and maintained positive outlook provided the catalyst for the stock's significant intraday gain.